Core Insights - Klotho Neurosciences, Inc. has allowed its Letter of Intent with Turn Biotechnologies to expire, as the proposed transaction did not align with the company's long-term strategic plan [1][2] - The company will redirect its focus and resources towards advancing its Klotho anti-aging protein research pipeline and developing treatments that promise the greatest value for patients and shareholders [2] Company Overview - Klotho Neurosciences, Inc. is a biogenetics company dedicated to developing innovative, disease-modifying cell and gene therapies utilizing a protein derived from the patented "anti-aging" human Klotho gene [4] - The company aims to transform the treatment of neurodegenerative and age-related disorders, including ALS, Alzheimer's disease, and Parkinson's disease, through its proprietary cell and gene therapy programs [4] Market Context - The longevity medicine market is one of the fastest-growing global sectors, driven by an aging population projected to reach 2.1 billion by 2050 [3] - Healthcare costs are currently at 10% of global GDP and are expected to exceed $47 trillion by 2030, highlighting the significant opportunity in the longevity sector [3]
Klotho Neurosciences Announces Expiration of Letter of Intent